US spot crypto ETF inflows cool to $64.8m after $3.3bn week
US spot crypto ETF inflows fell about 80% from Friday, with Bitcoin, Ether, Solana and XRP funds taking in $64.8m combined on Monday, though all four kept their positive streaks.
Why it matters: The figures show demand for US spot crypto ETFs cooling sharply day on day while the longer inflow streaks across Bitcoin, Ether, Solana and XRP funds remain intact.
Key points
- US spot Bitcoin ETFs led Monday with $31.1m, followed by Ether at $17.1m, Solana at $12.7m and XRP at $3.96m.
- The same four categories drew about $331m on Friday and more than $3.3bn over the prior week, led by Bitcoin at $2.39bn.
- Bitcoin ETFs extended their inflow streak to eight sessions, Ether and Solana to seven and XRP to five, according to the reported data.
US spot crypto ETF inflows cooled on Monday, with the four main categories attracting about $64.8m combined, down roughly 80% from Friday, Cointelegraph reports. The pullback followed a week in which the same funds took in more than $3.3bn.
SoSoValue data showed US spot Bitcoin ETFs leading Monday with $31.1m, followed by Ether funds at $17.1m, Solana at $12.7m and XRP at $3.96m.
Monday inflows slow
Zcash ETFs added about $35m over the week before an $8.1m outflow on Monday.
Despite the slowdown, every category stayed in positive territory. Monday extended Bitcoin ETFs' net inflow streak to eight trading sessions, a run that has brought in about $3bn, including a 2026 high of nearly $1bn on 21 Sept. Ether and Solana funds each logged a seventh straight positive session, and XRP funds a fifth, with BlackRock's iShares Ethereum Trust, Bitwise's BSOL and Canary Capital's XRPC named as the main contributors.
Live updates on NewsFeeds:ETFsBitcoinDesk editor: Keshav Aggarwal (accountable for this page; this summary was not edited by hand)
How this was produced: an AI model wrote this summary of Cointelegraph’s report, which we credit and link above. Read our Editorial and AI policy. Spotted a mistake? See Corrections.
Not investment advice. Read the risk disclaimer.